hepatitis B – media

TREAT-B – Blood Test to Detect Hepatitis B Well in Advance

Viral hepatitis is a major global health issue since it is the seventh leading cause of death worldwide. Around half of hepatitis-related deaths reported are due to the hepatitis B virus infection, which is transmitted through blood and body fluids.
- Source: MedIndia
- 404
- July 18, 2018
blood test hepatitis B Researches
Assembly Biosciences Initiates Phase 2a Trial for its Lead HBV Core Inhibitor

U.S. based public biotechnology company, Assembly Bioscience revealed the launch of two randomized control phase 2a trials for its leading hepatitis B core inhibitor in a press release.
- Source: Healio
- 999
- July 17, 2018
Clinical Trials hepatitis B
Nonadherence to Hepatitis B Medicines Increases Risk of Hepatocellular Carcinoma, Cirrhosis and Mortality

Recent scientific data revealed that the nonadherence to hepatitis B medicines increases the risk for hepatocellular carcinoma and cirrhosis followed by mortality.
- Source: Healio
- 726
- July 17, 2018
hepatitis B liver disease Researches
Recent Developments in HBV Diagnosis & Treatment

Hepatitis B virus (HBV) causes liver disease that leads to one million deaths throughout the world every year. Extensive research is going on to find the most effective, quick and accurate diagnostic measures followed by therapeutic solutions.
- Source: News Medical
- 678
- July 9, 2018
hepatitis B Researches
$20 Blood Test to Detect Hepatitis B

Hepatitis is considered as the seventh leading cause of death throughout the world, where half of the deaths occur due to hepatitis B viral infection. Early cost-effective diagnosis could help in treating the affected patients without any delay.
- Source: MedicalXpress
- 725
- July 4, 2018
blood test hepatitis B Researches
Dynavax Announces FDA Approval of HEPLISAV-B™ for Prevention of Hepatitis B in Adults

Dynavax Technologies Corporation (NASDAQ: DVAX) announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.
- Source: investors.dynavax
- 565
- November 13, 2017
FDA hepatitis B Heplisav-B

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.